NCT02864381View on ClinicalTrials.gov

Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma

PHASE2CompletedINTERVENTIONAL

Enrollment

144

Participants

Timeline

Start Date

September 1, 2016

Primary Completion Date

November 8, 2017

Study Completion Date

August 23, 2019

Conditions

Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma

Interventions

DRUG

Andecaliximab

800 mg administered via IV infusion

DRUG

Nivolumab

3 mg/kg administered via IV infusion

Trial Locations (34)

2076

Wahroonga

2640

Albury

3000

Leuven

4032

Debrecen

4818

Douglas

7000

Hobart

7100

La Louvière

9000

Ghent

10065

New York

16128

Genova

20132

Milan

28222

Majadahonda

29609

Brest

46845

Fort Wayne

47014

Meldola

51092

Reims

56126

Pisa

60637

Chicago

63110

St Louis

90095

Los Angeles

94158

San Francisco

94805

Villejuif

H-1097

Budapest

36-200

Brzozów

60-693

Poznan

02-781

Warsaw

08035

Barcelona

08003

Barcelona

BS2 8ED

Bristol

B15 2PR

Edgbaston

EC1A 7BE

London

WC1E 6BT

London

M20 4BX

Manchester

SM2 5PT

Sutton

Sponsors

Lead Sponsor

Gilead Sciences

All Listed Sponsors

lead

Gilead Sciences

INDUSTRY